<DOC>
	<DOCNO>NCT00379561</DOCNO>
	<brief_summary>This Phase 1 trial evaluate safety tolerability PSA-Activated PSA-PAH1 subject show biochemical failure either complete least one primary radiation therapy prostate cancer evidence recurrent local prostate cancer without metastasis .</brief_summary>
	<brief_title>PSA-Activated PSA-PAH1 Locally Recurrent Prostate Cancer</brief_title>
	<detailed_description>For information please contact Primary Investigator Protox Therapeutics , Inc .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>18 year age old Histologically proven prostate adenocarcinoma Completed full course definitive external beam radiation definitive brachytherapy ( ) primary therapy diagnose prostate cancer least one year prior enrollment Subject must least one available PSA measurement take 60 day follow primary therapy , later 2 month prior screen visit ( measurement serve first time point compute screen value PSA double time ) Subject 's PSA doubling time screen must &gt; 3 month ( double time compute compare early available PSA 60 day follow subject 's primary therapy later 2 month prior screen visit , PSA measurement obtain screen visit ) Within one year prior enrollment : Demonstrated `` biochemical failure , '' determine three consecutive increase PSA least 2 week apart Multiplesite biopsyconfirmed local recurrence prostate cancer Within 3 month prior enrollment : No evidence metastatic disease include bone metastases bone scan , lymph node , lung , liver soft tissue metastasis CT MRI scan evidence metastatic disease No receipt androgen ablation therapy [ Note : Subjects may receive androgen ablation therapy past , within 3 month prior enrollment . No subject remove androgen ablation therapy prior trial permit/facilitate eligibility trial . ] Within 30 day prior enrollment : Prostate gland weigh less 40 g estimate basis CT/ultrasound data Serum testosterone castrate range ( &gt; 1 ng/dL ) PSA level le 20 ng/mL Eastern Cooperative Oncology Group ( ECOG ) score 02 Written inform consent Adequate organ function evidence : Any history active malignancy prostate cancer Have active viral , bacterial fungal infection require systemic therapy Prior biological , immunological chemotherapy prostate cancer Receiving concurrent medication prostate cancer Received primary therapy prostate cancer , definitive external beam radiation concomitant brachytherapy Prior history metastatic prostate cancer Treatment investigational therapy within 12 month prior enrollment could produce compromise immune system , receipt immunosuppressive drug include corticosteroid ketoconazole within 1 month prior enrollment , history immunodeficiency disease Recurrence prostate cancer within 6 month initiation primary radiotherapy Active heart , liver , lung , renal disease , active infection serious uncontrolled illness Positive antibody test screen HIV1 , HIV2 , HTLV1 , HTLV2 , Hep B , Hep C Unable unwilling return require visit followup examination Have chronic indwelling Foley catheter obstructive uropathy Received salvage external beam radiotherapy and/or salvage seed brachytherapy prior enrollment Received prior treatment PSAPAH1 ( subject may redo protocol ) Men unwilling use condom duration study ( 3 month ) prevent pregnancy , avoid semen contact partner .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Recurrent Prostate Cancer</keyword>
	<keyword>Non-Metastatic prostate cancer</keyword>
	<keyword>Recurrent Localized Prostate Cancer Biochemical Failure</keyword>
</DOC>